Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: J Immunol. 2015 Dec 30;196(3):1366–1375. doi: 10.4049/jimmunol.1401838

Figure 5. miR-34a negatively regulates Mø SIRT1 expression and SIRT1 enhances efferocytosis.

Figure 5

A. Total RNA was harvested from AMø of wt mice and miR-34a+/− mice and SIRT1 mRNA expression was assessed by quantitative real-time RT-PCR, relative to GAPDH. B. Resident AMø from wt mice were treated in chamber-slides with the SIRT1-agonist resveratrol (10 μM for 24 h), exposed to AC and then efferocytosis was measured by microscopy. C–E. Resident PMø from wt mice were treated in chamber-slides with the SIRT1-antagonists (C) EX-527 (10 μM for 24 h) or (D, E) sirtinol (10 μM for 24 h), exposed to AC for 90 min, washed using a systematic protocol, stained using H&E and then efferocytosis was measured by microscopy. (F, G) Resident PMø from wt mice were treated in chamber-slides with the SIRT1-antagonist sirtinol (10 μM for 24 h), exposed to Ig-opsonized SRBC for 60 min, washed using a systematic protocol, stained using H&E and then FcγR-mediated uptake was measured by microscopy. Representative photomicrographs (D, F) are H&E-stained at 1000 X magnification. Data in all graphs are mean ± SEM from at least four replicates from two or more independent experiments. *, p<0.05; **, p<0.01 by Student t test.